BLRX Earnings Prediction
The chart below shows how BLRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BLRX sees a +4.24% change in stock price 10 days leading up to the earnings, and a -1.24% change 10 days following the report. On the earnings day itself, the stock moves by -3.15%. This data can give you a slight idea of what to expect for the next quarter's release.
BLRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
4.94M
--
--
Gross Margin
83.37%
--
--
Operating Margin
-108.98%
--
--
Net Margin
-117.78%
--
--
EPS
-0.00
-100.00%
--
No Data Available
BLRX Earnings Analysis
BioLineRX Ltd Corporation (BLRX.O) Earnings Conference Call
Positive
Licensing Agreement Impact: The company announced a significant licensing agreement with Ayermid Limited, which includes a $10 million upfront payment and potential commercial milestones of $87 million, enhancing cash flow and operational capacity.
Cost Reduction Strategy: The agreement allows BioLineRx to return to its drug development roots with a streamlined organization, expected to reduce annual cash burn by more than 70% effective January 1, 2025.
Market Share Milestone Achieved: The company achieved a 10% market share milestone of total CxCR4 inhibitor usage in the U.S., indicating strong market penetration and acceptance of its product.
Development Expenses Decrease: BioLineRx reported a decrease in development expenses for the three months ended September 30, 2024, to $2.6 million, compared to $2.7 million for the same period in 2023, reflecting effective cost management.
Market Leadership in Transplants: The company has secured approximately 40% of all transplant procedures in the U.S. by the end of the third quarter, demonstrating strong operational performance and market leadership.
Negative
Quarterly Revenue Comparison: Total revenue for the three months ended September 30, 2024 was $4.9 million, with no revenue recorded during the third quarter of 2023.
No Cost of Revenue: The company did not record any cost of revenue during the third quarter of 2023, reflecting a lack of operational activity.
Net Loss Decline: Net loss for the three months ended September 30, 2024 was $5.8 million compared to a net loss of $16 million for the same period in 2023, indicating a significant decline in financial performance.
Sales and Marketing Expense Decrease: Sales and marketing expenses for the three months ended September 30, 2024 were $5.5 million compared to $8.1 million for the same period in 2023, showing a decrease in investment in growth initiatives.
R&D Expense Decrease: Research and development expenses for the three months ended September 30, 2024 were $2.6 million, a decrease from $2.7 million for the same period in 2023, indicating reduced investment in innovation.
BLRX FAQs
How does BLRX typically perform around its earnings report dates?
Is BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BLRX Earning Call Sentiment
BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BLRX.O
-1.43%Positive
The earnings call presents a mixed outlook. Financial performance shows improvement with reduced net loss and increased revenue, but concerns about competitive pressures and economic factors persist. The Q&A highlighted uncertainties, particularly around revenue timelines from China. The company's strategic initiatives, like APHEXDA's market expansion, are promising, but supply chain challenges and debt obligations remain risks. Overall, the sentiment is neutral, with balanced positive and negative factors.